Basit öğe kaydını göster

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

dc.contributor.authorSapmaz, Perihan
dc.contributor.authorKonuk, Numan
dc.contributor.authorOrtancil, Ozgur
dc.contributor.authorBostanci, Bora
dc.contributor.authorKiran, Sibel
dc.date.accessioned2021-03-03T10:45:58Z
dc.date.available2021-03-03T10:45:58Z
dc.date.issued2010
dc.identifier.citationKonuk N., Ortancil O., Bostanci B., Kiran S., Sapmaz P., "A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study", KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.20, sa.1, ss.29-37, 2010
dc.identifier.issn1017-7833
dc.identifier.othervv_1032021
dc.identifier.otherav_247524fd-c3b2-4163-acf2-b1833496f6ed
dc.identifier.urihttp://hdl.handle.net/20.500.12627/29422
dc.identifier.urihttps://doi.org/10.1080/10177833.2010.11790631
dc.description.abstractObjective: Fibromyalgia (FM) is a chronic debilitating disorder that results in millions of dollars of heathcare costs and lost wages each year worldwide. It is a significant public health concern and new treatments are needed. In this study, we aimed to compare the effectiveness of a widely used tricyclic antidepressant for FM (amitryptylline) and one that has not yet been widely used (reboxetine) for FM in a within-subject pre-posttreatment design. Additionally, since noradrenaline (NA) is thought to play a relevant role in the antinociceptive mechanisms, we also aimed to examine the effectiveness of reboxetine as a selective NA reuptake inhibitor (NARI) in patients with fibromialgia.
dc.language.isoeng
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPsikiyatri
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.titleA Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study
dc.typeMakale
dc.relation.journalKLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
dc.contributor.departmentZonguldak Bülent Ecevit Üniversitesi , ,
dc.identifier.volume20
dc.identifier.issue1
dc.identifier.startpage29
dc.identifier.endpage37
dc.contributor.firstauthorID64871


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster